ARTICLE | Clinical News
Aerosolized Alpha-1 antitrypsin: Phase II/III data
May 19, 2014 7:00 AM UTC
Top-line data from a double-blind, European and Canadian Phase II/III trial in 168 patients with AAT deficiency showed that twice-daily 160 mg inhaled AAT missed the primary endpoint of improving time...